Gastro-oesophageal Adenocarcinoma (DBCOND0137329)

Identifiers

Synonyms

Gastroesophageal Adenocarcinoma

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT04779151	Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab	Dostarlimab Niraparib	treatment	2	suspended
NCT04774367	Evaluation of the Reliability of the Determination of MisMatch Repair Deficiency Status by Endoscopic Biopsies in Oesophagus and Gastric Adenocarcinoma.	No drug interventions	other	Not Available	not_yet_recruiting
NCT06043427	Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma	Paclitaxel Ramucirumab Zanidatamab	treatment	2	recruiting
NCT06445972	Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)	Paclitaxel Ramucirumab Sacituzumab tirumotecan	treatment	1 / 2	recruiting
NCT06469944	Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)	Capecitabine Fluorouracil Leucovorin Levoleucovorin Pembrolizumab Sacituzumab tirumotecan	treatment	1 / 2	recruiting
NCT05029882	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab	Bevacizumab TAS-102 Tipiracil Trifluridine	treatment	1	recruiting
NCT05152147	A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers	Capecitabine Cisplatin Fluorouracil Oxaliplatin Tislelizumab Trastuzumab Zanidatamab	treatment	3	recruiting
NCT05977322	A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.	Lutetium Lu-177	treatment	1	recruiting
NCT01045421	Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies	Alisertib	treatment	1 / 2	completed
NCT00073502	Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer	OSI-7904L	treatment	2	completed
NCT01757171	Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma	Cabazitaxel	treatment	2	completed
NCT04602117	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer	Paclitaxel Trastuzumab duocarmazine	treatment	1	withdrawn
NCT05986227	The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):	Toripalimab	treatment	1 / 2	not_yet_recruiting
NCT03639714	A Study of a Personalized Neoantigen Cancer Vaccine	Ipilimumab Nivolumab	treatment	1 / 2	completed
NCT04021108	Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)	Nivolumab	treatment	2	active_not_recruiting
NCT04712721	Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.	No drug interventions	other	0	terminated
NCT03794128	A Study of Personalized Neoantigen Cancer Vaccines	No drug interventions	Not Available	Not Available	completed
NCT05733689	Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)	Docetaxel Fluorouracil Irinotecan Leucovorin Nivolumab Pembrolizumab	treatment	1	not_yet_recruiting
NCT01182610	Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma	Carboplatin Fluorouracil Paclitaxel Panitumumab	treatment	2	terminated